ARVINAS, INC.

Arvinas, Inc. announced that its management will host a live webcast to review second quarter 2026 financial results and provide a corporate update. The event is scheduled for Tuesday, August 4, 2026, at 8:00 a.m. ET. Interested parties can access the webcast through the "Events and Presentations" section on the investor page of the company's website, with a replay available afterward.

Arvinas, Inc. announced that its Chief Medical Officer, Dr. Noah Berkowitz, will depart from his employment, effective July 3, 2026. The company has begun a search for a replacement. In connection with his departure, Dr. Berkowitz entered into a separation agreement entitling him to severance benefits, including nine months of continued base salary and health coverage premiums, along with accelerated vesting of certain restricted stock units.

Arvinas, Inc., Pfizer Inc., and Rigel Pharmaceuticals, Inc. received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, making their license agreement for VEPPANU (vepdegestrant) effective. As a result, Rigel has paid a $70.0 million upfront payment to Arvinas and Pfizer. The companies are also eligible for an additional $15.0 million upon successful completion of transition activities, up to $320.0 million in contingent milestone payments, and tiered royalties on worldwide net sales. All payments will be split evenly between Arvinas and Pfizer.

Arvinas, Inc. announced its participation in the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both backed by The Michael J. Fox Foundation. This collaboration will support the advancement of ARV-102, Arvinas' investigational PROTAC designed to target and degrade LRRK2 for potential treatment of neurodegenerative diseases like Parkinson's and progressive supranuclear palsy (PSP). The initiatives aim to deepen understanding of LRRK2 biology and accelerate therapeutic development through collaborative research and shared resources.

Arvinas, Inc. announced a strategic reprioritization of its portfolio, including plans to seek an out-licensing agreement for ARV-806 for any additional clinical trials beyond the ongoing Phase 1 monotherapy dose escalation. The company intends to complete the Phase 1 trial and share clinical data in 2026. Arvinas also affirmed that its cash, cash equivalents, and marketable securities as of March 31, 2026, are sufficient to fund operations into the second half of 2028. An Investor Presentation will be used at upcoming meetings, including the Jefferies Global Healthcare Conference.

Arvinas, Inc. announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, at 9:55 a.m. ET. A live audio webcast of the presentation will be accessible via the company's website. Arvinas is a clinical-stage biotechnology company pioneering protein degradation therapies, including the FDA-approved PROTAC, VEPPANU, developed with Pfizer Inc., and several other investigational drugs in clinical development.

Arvinas, Inc. announced its fourth annual Arvinas Impact Day, a company-wide day of service where employees volunteered across Connecticut, Greater Boston, and other locations. The event reflects the company's commitment to patients and supporting local communities. Employees participated in various projects, including preparing meals, creating blankets for hospital stays, and beautifying spaces for several non-profit organizations.

Arvinas announced its first quarter 2026 financial results and a significant corporate update, highlighted by the FDA approval of VEPPANU (vepdegestrant), the first PROTAC therapy, for advanced breast cancer. The company also entered into an exclusive global license agreement with Rigel Pharmaceuticals for VEPPANU. Financially, Arvinas reported a Q1 2026 net loss of $57.6 million on revenues of $15.6 million, a substantial decrease from the prior year, primarily due to changes in collaboration agreement revenue recognition. The company's cash, cash equivalents, and marketable securities stood at $614.9 million, providing a cash runway into the second half of 2028, and it also announced the appointment of Randy Teel as its new CEO.

Arvinas and Pfizer have entered into a license agreement with Rigel Pharmaceuticals for the exclusive global development, manufacturing, and commercialization rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC estrogen receptor degrader for advanced breast cancer. Under the terms, Rigel will pay Arvinas and Pfizer an aggregate of $70 million upfront and an additional $15 million upon completion of transition activities, totaling $85 million. The agreement also includes up to $320 million in potential development, regulatory, and commercial milestone payments, plus tiered royalties on worldwide net sales. Rigel will be responsible for the U.S. launch and commercialization, while Arvinas and Pfizer will contribute to ongoing development activities, with Rigel contributing up to $40 million towards these.

Arvinas announced the landmark FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ESR1-mutated, ER+/HER2- advanced breast cancer, and subsequently licensed its exclusive global rights to Rigel Pharmaceuticals. The company reported a Q1 2026 net loss of $(57.6) million on revenue of $15.6 million, with the revenue decrease primarily due to changes in collaboration cost estimates. Arvinas also provided positive updates on its pipeline, including promising Phase 1 data for ARV-102 in Parkinson's disease and the initiation of new clinical trials, while maintaining a strong cash position expected to fund operations into 2H 2028.